Skip to main content
. 2011 Jan 25;19(4):650–657. doi: 10.1038/mt.2010.312

Figure 4.

Figure 4

Combining vvCCL5 and DC1 therapies. (a) Mice bearing MC38 tumors were treated with DC1 vaccine loaded with MC38 lysate (or phosphate buffered saline (PBS)) and 48 hours later with vvCCL5 (or PBS). In vivo CTL assays were performed 7 days after different treatments to assess the levels of antitumor cytotoxic T lymphocyte response produced (n = 3 mice/group). (b) Mice were treated as before, with subsequent tumor volume determined by caliper measurements. vvCCL5 and DC1 vaccine combination results in significantly enhanced tumor responses relative to either therapy alone (P < 0.05, days 13–20) (n = 10/group). (c) Tumors treated as before were dissociated and single cell suspensions stained with anti-CD4 antibody; anti-NK1.1 antibody or anti-CD8 antibody and percentage of positively stained cells determined by flow cytometry (n = 3 or 4). DC, dendritic cell; NK, natural killer; TIL, tumor infiltrating lymphocyte.